Indian space agency's rocket fails to deploy satellite for Earth observation
The Indian Space Research Organization's EOS-09 spacecraft lifted off atop a Polar Satellite Launch Vehicle rocket from Satish Dhawan Space Center in Sriharikota at 5:59 a.m. local time Sunday. There have been 101 launches from Sriharikota, which is 1417 miles from New Delhi, including three to the moon and one to Mars.
The satellite was lost because of an issue with the third stage of the rocket about six minutes after launch.
"Third stage, motor started perfectly, but during the functioning of the third stage, we are seeing an observation, and the mission could not be accomplished," ISRO Chairman V. Narayanan said in a televised statement after the launch. "Third stage, motor started perfectly, but during the functioning of the third stage, we are seeing an observation, and the mission could not be accomplished. After analysis, we shall come back."
ISRO posted on X that "the mission could now be accomplished.
The 3,735-pound satellite was to be deployed from the upper stage about 18 minutes after liftoff at an altitude of 332 miles.
This was to be India's ninth mission in India's Earth Observation Satellite series.
The satellite included a synthetic aperture radar payload, which had been been successfully deployed in other missions.
The satellites can observe Earth day and night, including cloud cover.
India Today noted the round-the-clock, reliable intelligence is significant among security concerns along India's borders with Pakistan and China.
India was the first country to land a spacecraft near the moon's south pole in 2023. This is an arrea scientists believe could hold reserves of frozen water.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
UPI
6 hours ago
- UPI
Gilmour Space again delays launch of Australia's first orbital rocket
July 2 (UPI) -- The Australian aerospace firm Gilmour Space has again delayed the launch of its Eris 1 rocket, the country's first orbital rocket. Gilmour Space said Wednesday that it was standing down from a planned launch of what would be the first test flight of the rocket. "We've made the tough call to postpone this week's launch," the company said in a statement. It said the pause would give them a longer and more flexible launch window, and the team "a chance to rest after an intense few weeks of testing and prep." The company said the new launch window would depend on weather conditions and approval from regulators but that the next launch window is likely no earlier than July 16. On Monday, the company had said that the rocket was on the launch pad but that the winds weren't favorable for a launch. Gilmour Space had previously sought to launch the rocket on May 15 but encountered problems during routine shutdown procedures. At the time, the rocket's payload fairing -- a protective cone for the payload at the nose of the rocket -- unexpectedly separated from the launch vehicle. The cause of the incident went unexplained until May 30 when Gilmour Space revealed that the separation was caused by an unexpected power surge traced to electrical feedback during the vehicle's shutdown sequence. "No, it wasn't a cockatoo," the company said at the time. The company was founded by brothers Adam and James Gilmour in 2015 and now has more than 200 employees.
UPI
8 hours ago
- UPI
Study: Statins could prevent tens of thousands of heart attacks, strokes
More than 39,000 deaths, nearly 100,000 non-fatal heart attacks and up to 65,000 strokes in the U.S. could be prevented if people eligible for statins and other cholesterol-lowering drugs were taking them, researchers reported Monday. Adobe stock/HealthDay July 2 (UPI) -- Tens of thousands of people suffer needless heart attacks and strokes every year because they aren't taking cholesterol-lowering drugs, a new study says. More than 39,000 deaths, nearly 100,000 non-fatal heart attacks and up to 65,000 strokes in the U.S. could be prevented if people eligible for statins and other cholesterol-lowering drugs were taking them, researchers reported Monday in the Journal of General Internal Medicine. Nearly half of Americans (47%) who have never had a heart attack or stroke are eligible to take statins under U.S. guidelines, researchers found. But fewer than a quarter (23%) of them have been prescribed the life-saving drugs, results show. A substantial number of heart attack or stroke survivors also aren't taking the drugs, even though all are eligible for them under U.S. guidelines, researchers said. "These results add to a growing body of evidence that there are important shortcomings in the quality of care for common and costly chronic diseases such as high cholesterol, and that addressing those shortcomings would yield major public health benefits," lead researcher Dr. Caleb Alexander, a professor of epidemiology at the Johns Hopkins Bloomberg School of Public Health, said in a news release. For the study, researchers analyzed data from nearly 5,000 U.S. adults between 40 and 75 years of age who took part in an annual U.S. Centers for Disease Control and Prevention health survey between 2013 and 2020. The survey included data on the people's "bad" LDL cholesterol levels and their overall heart health risk profile. Researchers used that info to determine whether they'd be eligible to take cholesterol-lowering drugs under current guidelines. Even people who had suffered a prior heart attack and stroke -- and thus are at higher risk for a follow-up event -- aren't always prescribed statins, researchers found. Only about two-thirds (68%) are taking statins, even though all are eligible for the drugs under the guidelines, results show. Along with warding off heart attacks and strokes, properly prescribed statins also could prevent every year nearly 88,000 heart bypass surgeries and procedures to reopen blocked or clogged arteries, researchers estimated. If everyone eligible for statins took them, researchers estimate that average LDL cholesterol levels would drop sharply and the risk of heart attack or stroke would fall by up to 27%. Preventing heart attacks and strokes through cholesterol-lowering drugs also could save more than $30 billion in annual medical costs for the U.S., researchers estimate. "Several factors account for the gaps that we document," Alexander said. "They include differences in clinician training, patient preferences, barriers to accessing care, financial incentives that don't always support best practices, and the difficulty of putting clinical guidelines into practice in busy, real-world settings." Better patient education and improved screening methods could make sure the right people are taking the statins they need, researchers said. "High cholesterol is an important chronic health condition that silently claims far too many lives -there are millions of people walking around with this condition that don't even know they have it, and then when it is recognized it too often goes undertreated," senior author Dr. Seth Martin, a professor of cardiology at the Johns Hopkins University School of Medicine, said in a news release. "Evidence-based action is critical to close the gap and prevent devastating cardiovascular events," he said. More information Harvard Medical School has more on statins. Copyright © 2025 HealthDay. All rights reserved.
Miami Herald
10 hours ago
- Miami Herald
‘Inverse' vaccines may hold key to challenge autoimmune diseases
NEW YORK, June 30 (UPI) -- For the millions of Americans battling autoimmune disorders, new hope may be on the horizon in the form of reverse or inverse vaccines -- injections that target a specific part of the immune system. experts told UPI. However, these injections work differently from conventional immunizations like the flu shot and currently available immunosuppressant treatments for autoimmune conditions. They work by targeting only the specific part of the immune system that's behind diseases such as lupus, multiple sclerosis, psoriasis, rheumatoid arthritis and Type 1 diabetes, the experts say. 'Inverse vaccines are being developed to treat undesired immune responses, [and] for these situations, the body is reacting to something that is not dangerous,' said Lonnie Shea, a researcher in biomedical engineering at the University of Michigan who has studied inverse vaccines and worked on some of the key technology behind them. 'A vaccine activates an immune response to a specific antigen,' Shea told UPI via email. Inverse vaccines are being developed to treat undesired immune responses, [and] for these situations, the body is reacting to something that is not dangerous. Essentially, an inverse vaccine 'aims to decrease the response to a specific antigen, like insulin in Type 1 diabetes,' he added. First line of defense When healthy, the immune system is the body's first line of defense against diseases such as cancer and infections caused by viruses and bacteria, according to the National Institutes of Health. However, if the immune system isn't working properly, it can erroneously attack healthy cells, tissues and organs, causing autoimmune diseases that can affect any part of the body, weakening function and potentially leading to death, the NIH says. More than 80 autoimmune diseases are known, some of which are caused by exposure to environmental toxins and have no discovered cure. At least 15 million people in the United States, or about 5% of the population, have an autoimmune disease, the agency reports. Although no cure exists for these conditions, symptoms can be managed with drugs called immunosuppressants, which as the name suggests 'broadly reduces your immune system response,' Shea said. These drugs, which are typically administered via monthly injections, can have significant side effects, including making those taking them more susceptible to infections, according to the NIH. Many people taking them also have to be careful taking traditional vaccines, such as flu shot or COVID-19 shots because of their impact on the immune system. Training the immune system Developed by researchers at the University of Chicago and elsewhere, inverse vaccines use synthetic nanoparticles attached to specific disease-related proteins, or antigens, to train certain parts of the immune system to behave differently, limiting the attacks that cause autoimmune diseases, neurologist Dr. Lawrence Steinman said. With the inverse vaccines currently being studied, the nanoparticles are designed to mimic human cell death, which is a normal process in the human body, according to the 2021 study that first documented their effectiveness in people with celiac disease, another autoimmune disorder. Dying cells are considered foreign bodies, but the human immune system knows not to attack them. As a result, with the nanoparticles in inverse vaccines, the immune system can be trained not to attack them, or the proteins attached to them, which effectively short-circuits the process behind autoimmune diseases, Steinman said. 'Instead of immunizing the recipient to a viral infection, the inverse vaccine tolerizes the immune system, so it will not attack our own tissues,' Steinman, who has written about inverse vaccines, told UPI in an email. Several companies are running clinical trials of inverse vaccines, including Cour Pharma, which recently completed successful phase 2 clinical trials for their use in celiac disease and another autoimmune disease, primary biliary cholangitis, according to Shea at the University of Michigan, one of the researchers who started the company. Additional trials -- phase 2 studies are the second stage in the drug research and development process -- are starting for myasthenia gravis and Type 1 diabetes, he added. Although more research is needed before the shots become available, a process that could take five years or more, inverse vaccines offer key advantages, Shea said. For example, unlike immunosuppressants with their monthly dosing, the effects of inverse vaccines appear to last longer, perhaps for as much as a year, similar to conventional vaccines, research suggests. They may also work for people with severe, life-threatening allergies, such as peanut allergies, according to Shea, who has published a study in this area using mice. However, there's also the 'risk that instead of tolerizing the human immune system to the target, the process induces conventional immunization, which would make autoimmune conditions like Type 1 diabetes and multiple sclerosis worse,' Steinman said. However, 'We have come close to success in some early-stage trials,' he said 'Thus far, none of the results are sufficiently robust for submission in the FDA approval process.' Copyright 2025 UPI News Corporation. All Rights Reserved.
